BOSTON, Sept. 27, 2016 /PRNewswire/ -- DarioHealth Corp.
(NASDAQ:DRIO), a leader in digital health and mobile health
solutions and the developer of the Dario™ Smart Diabetes Management
Solution, today announced the launch of an online store in
Canada. This is in collaboration
with A&D Medical, a global leader in connected health and
biometric measurement devices and services, and Bayshore Specialty
Rx Ltd.'s online pharmacy Diabetes Express.
While Dario is widely accepted under reimbursement in
Canada, this partnership with
Bayshore Specialty Rx Ltd. allows for a complete online experience
for Dario products and supplies. The full service provided by
Diabetes Express, a division of Bayshore Specialty Rx Ltd.,
includes all handling of the prescription and interaction with the
insurers. The new online store's URL will be http://mydario.ca and
be operated in collaboration with DarioHealth, Diabetes Express and
A&D. DarioHealth is responsible for the digital marketing and
Diabetes Express will handle reimbursement and the prescription
process.
"We are thrilled with these partnership agreements and our
launch of a Canadian online store as an implementation of our
strategy to make the life of people with diabetes easier," said
Erez Raphael, DarioHealth's Chairman
and Chief Executive Officer. "Our team at DarioHealth has developed
strong direct digital marketing capabilities and combined with our
partners' complete end-to-end digital pharmacy capabilities,
including prescription processing and reimbursement, we will offer
a complete and robust offering to the diabetes population in
Canada."
Aleksandra Filipovic, Director of
Bayshore Diabetes, stated, "I am confident that the combination of
a highly-digital and engaging product like Dario and our online
direct to consumer platform will provide an extremely valuable
experience for patients with diabetes."
Terry Duesterhoeft, President and
CEO of A&D, stated, "Dario is one of the featured products in
our Canadian portfolio and we look forward to boosting Dario sales
through our digital pharmacy platform."
About A&D Medical
Since 1977, A&D Medical has manufactured and distributed a
full line of advanced biometric monitoring solutions including
blood pressure monitors, weight scales, activity monitors, and
other health monitoring devices for consumer and professional use.
A&D Medical is the worldwide leader in connected health and
biometric measurement devices and services for consumer wellness
and chronic condition management, marketing under the A&D brand
globally and also the LifeSource brand in North America. A&D Medical is a division
of A&D Company, a global manufacturer of measurement equipment,
with operations in Asia,
Europe, Australia, Russia, North
America, and South
America.
For general information about A&D Medical, please visit
www.andonline.com.
About Bayshore Specialty Rx Ltd.
A division of Bayshore HealthCare, a premier healthcare provider
and a proudly Canadian company since 1966, Bayshore Specialty
Rx Ltd., provides a wide-range of patient support programs
that include services such as data management support, specialty
nursing, specialty pharmacy, reimbursement services and call
centre. Bayshore operates more than 45 infusion clinics and
pharmacies across the country with the goal to improve patient
outcomes through integrated support of complex therapies and
community services.
Diabetes Express, A Division of Bayshore Specialty Rx Ltd., is
the diabetes focused business unit which works directly with
manufacturers, diabetes education clinics and patients to provide
the best diabetes product support, access and information within
every province in Canada.
About DarioHealth Corp.
DarioHealth is a leader in digital health self-management
solutions. DarioHealth delivers the ability to combine and analyze
consumer health data to personalize treatment and advance medical
knowledge. The Dario™ Smart Diabetes Management Solution is
a platform for diabetes management that combines the Dario Blood
Glucose Monitoring System all-in-one blood glucose meter, native
smart phone app, website portal and a wide variety of treatment
tools to support more proactive and better informed decisions by
users living with diabetes, their doctors and healthcare
systems. Having recently launched in the largest market in
the world for glucose monitoring, U.S. sales are expected to have a
significant impact on revenues and gross margins. With marketing
clearance in Europe and the U.S.,
the Dario iOS mobile app recently launched with reimbursement in
the United Kingdom, Australia, Israel, Italy, and Canada, and has also launched in New Zealand, Netherlands, Italy, and Belgium. For more
information, visit http://mydario.investorroom.com/
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate" or "continue" are intended to identify
forward-looking statements. For example, when the Company
describes the impact on sales and distribution from the new online
store, and says that U.S. sales are expected to have a significant
impact on the Company's revenues and gross margins, it is using
forward-looking statements. Readers are cautioned that certain
important factors may affect the Company's actual results and could
cause such results to differ materially from any forward-looking
statements that may be made in this news release. Factors that may
affect the Company's results include, but are not limited to,
regulatory approvals, product demand, market acceptance, impact of
competitive products and prices, product development,
commercialization or technological difficulties, the success or
failure of negotiations and trade, legal, social and economic
risks, and the risks associated with the adequacy of existing cash
resources. Additional factors that could cause or contribute to
differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Corporate and Media Contact
Shmuel Herschberg
Marketing Director
Shmuel@mydario.com
+1-800-896-9062
DarioHealth Investor Relations Contact
Hayden IR
Rob Fink / Brett Maas
DRIO@HaydenIR.com
+1-646-415-8972 / +1-646-536-7331
Logo - http://photos.prnewswire.com/prnh/20160926/411823LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/dariohealth-launches-new-digital-platform-and-online-store-in-canada-300334045.html
SOURCE DarioHealth Corp.